NeuroGenica

NeuroGenica is a pre-clinical stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for neurodegenerative diseases. The company leverages a proprietary discovery platform to identify compounds that promote neuroprotection and neuroregeneration, specifically targeting the underlying mechanisms of neuronal death. NeuroGenica's primary therapeutic focus includes Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). By developing disease-modifying therapies, the company aims to address the significant unmet medical need in the aging population. Headquartered in Basel, Switzerland, with operations in the United States, NeuroGenica is led by a team of experienced industry veterans from major pharmaceutical companies.